ReviewInternational journal of pharmaceutics: X2024
Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles.
Review in International journal of pharmaceutics: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Toxicity of nanostructures in drug delivery applications.Pharmaceutical science advances · 2026Review
- Thieno[3,2-International journal of molecular sciences · 2026Review
- Photodynamic Therapy Targeting Matrix Metalloproteases in Cancer: Standpoint for an Innovative Anticancer Strategy.Current issues in molecular biology · 2026Review
- [Exploration and application of nanotechnology in precision transarterial chemoembolization for hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Advances in green-synthesized magnetic nanoparticles for targeted cancer therapy: mechanisms, applications, and future perspectives.European journal of medical research · 2026Review
- EGFR-targeted tyrosine kinase inhibitors: advancements in cancer therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Copper/iron-based intelligent nanoparticles self-amplify apoptosis/ferroptosis/cuproptosis in colorectal cancer.Materials today. Bio · 2026Article
- Applying biotechnology to overcome cancer drug resistance and improve public health outcomes.Osong public health and research perspectives · 2026Article
- Nanocarrier-mediated CRISPR-Cas delivery: a novel approach against antibiotic-resistant superbugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Nanotechnology in Skin Cancer Therapy: Recent Progress in Targeted Delivery.The Kaohsiung journal of medical sciences · 2026Review
- Investigation of antimicrobial synergism of actinomycin derivatives fromTurkish journal of biology = Turk biyoloji dergisi · 2026Article
- Nanomaterial-enabled delivery of plant-derived bioactive metabolites for diabetic retinopathy: from evidence appraisal to preclinical translation.Frontiers in pharmacology · 2026Review
- Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy.Cell communication and signaling : CCS · 2025Review
- Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy.International journal of molecular sciences · 2025Review
- The Influence of Synthesis Parameters on the Properties of Dextran-Based Hydrogels for Colon-Targeted Antitumor Drug Delivery Part I: Room Temperature Synthesis of Dextran/Inulin Hydrogels for Colon-Targeted Antitumor Drug Delivery.Gels (Basel, Switzerland) · 2025Article
- Multifunctional gold nanoclusters as next-generation theranostic platforms for disease management.International journal of pharmaceutics: X · 2025Review
- Nanomedicine and nutraceutical-based nanocarriers for specific delivery to cancer stem cells: targeted drug delivery at the STEM frontier.Discover oncology · 2025Review
- Advances in Cell-Mediated Drug Delivery for Dermatologic Diseases: Mechanisms and Current Applications.Pharmaceutics · 2025Review
- Bio-Functional Nanomaterials for Enhanced Lung Cancer Therapy: The Synergistic Roles of Vitamins D and K.Journal of functional biomaterials · 2025Review
- Covalently Functionalized Halloysite-Calixarene Nanotubes for Injectable Hydrogels: A Multicavity Platform for Hydrophobic Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the leading cause of death globally, and conventional treatments have limited efficacy with severe side effects. The use of nanotechnology has the potential to reduce the side effects of drugs by creating efficient and controlled anticancer drug delivery systems. Nanoparticles (NPs) used as drug carriers offer several advantages, including enhanced drug protection, biodistribution, selectivity and, pharmacokinetics. Therefore, this review is devoted to various organic (lipid, polymeric) as well as inorganic nanoparticles based on different building units and providing a wide range of potent anticancer drug delivery systems. Within these nanoparticulate systems, chitosan (CS)-based NPs are discussed with particular emphasis due to the unique properties of CS and its derivatives including non-toxicity, biodegradability, mucoadhesivity, and tunable physico-chemical as well as biological properties allowing their alteration to specifically target cancer cells. In the context of streamlining the nanoparticulate drug delivery systems (DDS), innovative nanoplatform-based cancer therapy pathways involving passive and active targeting as well as stimuli-responsive DDS enhancing overall orthogonality of developed NP-DDS towards the target are included. The most up-to-date information on delivering anti-cancer drugs using modern dosage forms based on various nanoparticulate systems and, specifically, CSNPs, are summarised and evaluated concerning their benefits, limitations, and advanced applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.